Streptozotocin, which induces diabetes mellitus in experimental animals, has been reported to be taken up by ␤-cells by means of the glucose transporter 2 (GLUT2) and then reduce the cellular level of NAD ϩ , leading to necrosis of the ␤-cells. We investigated the effect of insulin pretreatment on the diabetogenic action of streptozotocin (60 mg/kg). Four groups of rats were studied: 1) a group that received streptozotocin (STZ), 2) a group that received insulin pretreatment and streptozotocin (INSϩSTZ), 3) a group that received insulin (INS), and 4) a control group (CTRL). Insulin treatment reduced the ␤-cell immunoreactivity (IR) of insulin and GLUT2, which, thus, was reduced in INSϩSTZ rats at the time of streptozotocin injection. In STZ rats, plasma insulin concentrations after 3 weeks as well as insulin concentrations in pancreatic tissue samples were significantly lower than those in CTRL rats [plasma, 274. 
concentrations in pancreatic tissue samples were significantly lower than those in CTRL rats [plasma, 274.3 Ϯ 101.9 vs. 1078.8 Ϯ 254.9 pmol/liter (P Ͻ 0.05); tissue, 0.46 Ϯ 0.02 vs. 117.0 Ϯ 28.4 nmol/g (P Ͻ 0.01)]. INSϩSTZ rats did not become hyperglycemic, and the plasma and tissue levels of insulin were higher than those in STZ rats [plasma, 538.3 Ϯ 80.1 vs. 274.3 Ϯ 101.9 pmol/liter (P ϭ 0.08); tissue, 0.46 Ϯ 0.02 vs. 37.90 Ϯ 2.13 nmol/g (P Ͻ 0.05)]. The immunohistochemical findings of insulin IR in the pancreatic tissues were in accordance with the results obtained by RIA. We conclude that exogenous insulin suppresses the expression of GLUT2 and insulin in ␤-cells, and this may prevent the diabetogenic effect of streptozotocin. (Endocrinology 138: 62-68, 1997) S TREPTOZOTOCIN, a N-nitroso derivative of d-glucosamine, has been widely used to induce experimental diabetes in various laboratory animals. It was originally isolated from cultures of Streptomyces Achromogenes in 1960 (1) . The glucose transporter 2 (GLUT2) is expressed in rodent ␤-cells of the pancreas, in the kidney, and the liver (2) (3) (4) . GLUT2 mediates the glucose uptake into ␤-cells (2) and has recently been suggested to mediate the cellular uptake of streptozotocin (3) . This may explain why ␤-cells especially are affected by the drug. Streptozotocin causes fragmentation of DNA in rat pancreatic ␤-cells through the formation of free alkylating radicals, leading to a reduction in the cellular levels of nucleotides and related compounds, particular NAD ϩ . This causes a rapid necrosis of the ␤-cells (5) (6) (7) (8) . Insulin therapy has been observed to render ␤-cells less vulnerable to immune aggression in diabetes-prone animals (9, 10) , and hyperinsulinemia in rats with insulinoma causing hypoglycemia results in reduced expression of GLUT2 on ␤-cells (3, 11) . Reduced GLUT2 expression might reduce the cellular uptake of streptozotocin into ␤-cells. We propose that insulin therapy may affect experimental diabetes induced by streptozotocin, possibly through down-regulation of GLUT2 and a reduced cellular need for NAD ϩ due to decreased ␤-cell activity. Thus, the aim of the present study was to investigate the effect of intensive insulin treatment on the diabetogenic action of streptozotocin.
Materials and Methods Animals
The animal studies were approved by the local animal committee of Copenhagen, Denmark. Eight-week-old female Wistar rats, weighing 200 -220 g (Panum Institute, Copenhagen, Denmark), were randomly allocated into four groups ( Fig. 1 ): 1) streptozotocin-induced diabetic (STZ), 2) insulin-treated before and 24 h after streptozotocin injection (INSϩSTZ), 3) insulin-treated control (INS), and 4) control (CTRL) rats. All animals were allowed free access to water and laboratory food (Altromin no. 1314, Altromin International, Lage, Germany).
Experimental diabetes
A single ip injection of 60 mg/kg streptozotocin (Sigma Chemical Co., St. Louis, MO) dissolved immediately before administration in freshly prepared 50 mm citrate buffer (pH 4.0) was given to the STZ and INSϩSTZ rats on day 0. The injections were given at 1600 h. Control animals received an equivalent volume of citrate buffer.
Insulin treatment
The INSϩSTZ and INS rats were treated daily for 7 days with a long acting heat-treated insulin preparation (Ultralente, pH 5.5, Novo-Nordisk, Bagsvaerd, Denmark). Both groups were treated with 40 IU/rat (200 mU/g BW⅐day) from days Ϫ5 to 0 and then on day 1 with 20 IU/rat if the blood glucose concentration was below 2 mmol/liter, but otherwise with 40 IU/rat. Insulin doses were 10 times higher than those recommended for treatment of diabetic rats (12) to ensure diminished activity of the ␤-cells but also survival of the rats despite the marked hypoglycemia.
Blood glucose and body weight
The blood glucose concentration was measured in blood from a tail vein in the morning in STZ rats on day Ϫ5 (n ϭ 12), daily from days 0 -3 (n ϭ 12), and on days 5, 7, 14, and 21 (n ϭ 6); in INSϩSTZ and INS rats daily from days Ϫ5 to 3 (n ϭ 12; INS, n ϭ 8 on day 3) and then on days 5, 7, 10, 14, and 21 (n ϭ 6; INS, n ϭ 4); and in CTRL rats on day Ϫ5 (n ϭ 12) and then at the same time points as INSϩSTZ and STZ rats from days 1-21 (n ϭ 8 from day 7) by a One Touch II instrument (Lifescan, Milpitas, CA), using the glucose oxidase method. The rats were weighed on the same days.
Tissue and blood samples for RIA
Tissue samples of pancreas were obtained on day 2 (n ϭ 4, all groups) and 21 (n ϭ 4, all groups) for extraction and subsequent RIA to measure both the acute and chronic effects of the treatment. The tissue samples were weighed and then immediately frozen in dry ice. Blood samples (n ϭ 4, all groups) were obtained on day 21. The blood samples were obtained by cannulation of the left ventricle of the heart, drained into ice-cold tubes containing 6 mmol/liter EDTA and 500 IU/ml aprotinin, and kept on ice until centrifugation within 30 min. Plasma was stored at Ϫ20 C until assay.
Tissue extraction
Pancreatic tissue specimens were homogenized and extracted in 4 vol acid-ethanol, as described by Newgard et al. (13) . After 2 h at 4 C, the extracts were centrifuged, and the clear supernatants were neutralized with ammonium hydroxide and then evaporated on a vacuum centrifuge (Speed-Vac, Heto, Hilleroed, Denmark). The samples were reconstituted in phosphate buffer (0.04 m; pH 7.4) containing in addition 2.9 g/liter NaCl, 10 mm EDTA, and human serum albumin (Behringwercke, Marburg, Germany) before analysis of insulin immunoreactivity. Insulin was measured using antiserum 2004, raised against porcine insulin (but having strong reactivity against rat insulin), rat insulins I and II (mixed in the same proportion in which they occur in the pancreas) as standard, and monoiodinated 125 I-labeled human insulin (generous gift from Novo Nordisk) according to the principles described by Albano et al. (14) .
Assays
Before all plasma measurements, 700 l plasma/sample⅐assay were extracted in 70% ethanol (vol/vol, final concentration). The supernatant was dried in a vacuum centrifuge and redissolved in phosphate buffer as described above. All plasma samples were assayed in duplicate. Insulin was measured as described above. Pancreatic glucagon was measured using antiserum 4305, monoiodinated 125 I-labeled glucagon (generous gift from Novo Nordisk), and highly purified porcine glucagon as standard (Novo Nordisk) (15, 16) . Antiserum 4305 requires the free COOH-terminus of glucagon for binding. Total glucagon (enteroglucagon and pancreatic glucagon) was measured using antiserum 4304, which cross-reacts with equal strength with all peptides that contain the glucagon sequence. The experimental detection limit for both assays was below 2 pmol/liter. The intra-and interassay coefficients of variation were below 10% and 20%, respectively, for insulin at a level of 500 pmol/liter.
Immunohistochemistry
Tissue samples for immunohistochemistry were obtained from the dorsal region of pancreas on day 0 (n ϭ 4, only INS group), 2 (n ϭ 4, all groups), 7 (n ϭ 4, all groups), and 21 (n ϭ 4, all groups). Tissue samples were immediately fixed by immersion into ice-cold, freshly prepared, buffered 4% paraformaldehyde. The fixed tissue samples of pancreas were embedded in paraffin and cut into 10-m sections using a microtome. The unlabeled antibody peroxidase-antiperoxidase technique was applied, as described by Sternberger (17) . Insulin antiserum (no. 2004), glucagon antiserum (no. 4304), and somatostatin antiserum (no. 1759 -6) were diluted 1:400 and 1:1600 and GLUT2 antiserum (East Acres Biologicals, Southbridge, MA) was diluted 1:1000 with 0.1 mol/liter phosphate buffer (pH 7.6) containing 0.1% human serum albumin. The sections were examined by means of a Zeiss microscope (Carl Zeiss, Oberkocken, Germany). The examiner of the histological sections was not aware of the origin of the specimens when evaluating the stained sections. Photographs were taken with Agfa-pan APX25 film (AgfaGevaert AG, Leverkusen, Germany).
Results and statistics
Results are expressed as the mean and sem (in Fig. 2, A and B, only mean values are shown). Nonparametric Mann-Whitney U test (twotailed) was used for comparison of groups. P Ͻ 0.05 was considered significant.
Results

Blood glucose concentration
Hyperglycemia ( Fig. 2A) was observed in the STZ rats within 48 h after administration. Four days after streptozotocin injection, the mean blood glucose concentration in the STZ rats was above 20 mmol/liter, and it remained at this elevated level throughout the 3 weeks of the study. The INSϩSTZ rats were hypoglycemic during the insulin treatment, but on day 5, the blood glucose concentration had returned to a normoglycemic level (day 5, 3.7 Ϯ 1.3 nmol/ liter; CTRL, 4.2 Ϯ 0.9 nmol/liter; P ϭ 0.28). Similar results were observed in the INS rats.
To study whether a shorter period of insulin-induced hypoglycemia could affect the diabetogenic action of streptozotocin to a similar degree as the longer insulin treatment used in the INSϩSTZ group, we investigated a fifth group of rats (short term hypoglycemia; n ϭ 12). This group was treated with insulin from days Ϫ1 to 1 with the same dose as that given to the INSϩSTZ and INS animals, and it was also injected with streptozotocin (60 mg/kg) on day 0. Blood glucose concentrations were 1.3 Ϯ 0.2 mmol/liter on day 0, 2.2 Ϯ 0.3 mmol/liter on day 3, 14.5 Ϯ 0.6 mmol/liter on day 5, 18.5 Ϯ 1.5 mmol/liter on day 14, and 20.8 Ϯ 0.5 mmol/liter on day 21 . These values were significantly (P Ͻ 0.01) different from that on day 5 compared to the CTRL group. 
Body weight
The body weight (Fig. 2B ) of the CTRL rats increased during the 3 weeks of the study from a mean of 212 Ϯ 2 to 243 Ϯ 7 g (P Ͻ 0.01). In contrast, the body weight of the STZ rats remained constant during the study (day Ϫ5, 213 Ϯ 2 g; day 21, 204 Ϯ 4 g; P ϭ 0.51). The INS and INSϩSTZ rats gained more weight than the CTRL rats during the period of insulin treatment.
RIA
The concentration of insulin in pancreatic tissue samples was measured on days 2 and 21 ( Table 1 ). The pancreatic concentration of insulin was significantly reduced (P Ͻ 0.01) in STZ, INSϩSTZ, and INS rats on day 2 compared to that in the CTRL group. On day 21, the concentration of insulin in STZ rats was significantly lower than those in INSϩSTZ, INS, and CTRL rats (P Ͻ 0.05, P Ͻ 0.05, and P Ͻ 0.01, respectively). In the INSϩSTZ group, the pancreatic concentration of insulin was reduced to 32% of the level in CTRL rats, but, on the other hand, it was significantly (P Ͻ 0.05) higher (80 times) than that in STZ rats. The concentration of insulin in tissue samples from INS rats on day 21 was not significantly different (P ϭ 0.38) from the CTRL value.
Immunohistochemistry
The GLUT2 immunoreactivity (IR) in the CTRL group (Fig.  3A) was localized to the cellular membranes of ␤-cells in the pancreatic islets. In INS rats, GLUT2-IR was considerably reduced on day 0 (Fig. 3B) . In the same group of rats, however, on day 7, 6 days after last dose of insulin, the level of GLUT2-IR (Fig. 3C ) was comparable to that in the CTRL group. In the INSϩSTZ group, GLUT2-IR was not detectable on day 2 (Fig. 3D) ; thereafter it reappeared, but at a lower intensity on day 7 than that in the CTRL rats (Fig. 3E ) and an intensity of GLUT2-IR on day 21 comparable to that in the CTRL group (Fig. 3F) .
In the CTRL rats, the insulin -IR ␤-cells (Fig. 4A ) were located centrally in the islets of Langerhans, whereas the glucagon-IR (Fig. 4B ) cells were located in the periphery of the islets.
In the STZ rats, the number of insulin-IR ␤-cells (Fig. 4C ) was markedly reduced; in most islets insulin-IR cells were completely absent. The amount of glucagon-IR cells (Fig. 4D) , was increased, and almost all remaining cells in the islets were ␣-cells.
In the INSϩSTZ rats, a slightly reduced or equal number of insulin-IR cells (Fig. 4E) and a slightly increased amount of glucagon-IR cells (Fig. 4F) were found in comparison to the CTRL group.
There were few somatostatin-IR cells in all groups of rats. They were located in the periphery of the islets, and the amount of somatostatin-IR cells was unchanged among the various groups (data not shown).
Plasma insulin concentration
The plasma concentration of insulin (Table 2 ) on day 21 was significantly lower (P Ͻ 0.05) in STZ rats than that in CTRL rats. The plasma concentration of insulin in INSϩSTZ rats was not significantly different from that in CTRL rats (P ϭ 0.14), but tended to be higher than that in the STZ group (P ϭ 0.08). The level in the INS group was comparable (P ϭ 0.83) to that in the CTRL group. 
Plasma glucagon concentration
The plasma concentration of glucagon (Table 2 ) on day 21 was significantly increased (P Ͻ 0.05) in STZ rats compared to those in INSϩSTZ, INS, and CTRL rats. The increased concentration of total glucagon was due to a significant increment in enteroglucagon (P Ͻ 0.05) and, to a lesser degree, a significant increment in pancreatic glucagon (P Ͻ 0.05). 
Discussion
In the present study, insulin pretreatment of rats prevented the diabetogenic effect of streptozotocin. The protective effect of insulin against streptozotocin-diabetes is most likely due to the combination of a decreased activity of ␤-cells, a reduced cellular need for NAD ϩ , and a reduced number of GLUT2 transporters on the ␤-cells, which have been implicated as important factors in the diabetogenic effect of streptozotocin (3, 7, 8) .
The exact mechanism of the ␤-cytotoxic action of strepto- zotocin is still conjectural, although it has been intensely investigated. The GLUT2 transporter that mediates the glucose uptake into rodent ␤-cells (2) is assumed to also mediate the cellular uptake of streptozotocin (3). In contrast to GLUT2, GLUT1, an isoform of GLUT2 with very low or no affinity for streptozotocin as a transport substrate (3), is predominately expressed on human ␤-cells (18) . This may explain why human fetal pancreatic ␤-cells are resistant to the toxic effect of streptozotocin (19) and why patients with endocrine tumors treated with streptozotocin do not develop diabetes. Okamoto (5, 6) has shown that the streptozotocin-induced injuries in rodent ␤-cells provoke DNA repair mechanisms involving the action of the NAD ϩ -degrading enzyme poly(ADP-ribose) synthetase, and that the subsequent depletion of the cellular NAD ϩ pool depresses cell functions, leading to degeneration of ␤-cells (5) (6) (7) (8) 20) . In support of the suggested action of streptozotocin, inhibitors of poly(ADP-ribose) synthetase, e.g. nicotinamide and aminobenzamide, have been shown to prevent streptozotocin-diabetes through protection of the intracellular NAD ϩ pool (21, 22) . In the present study, short term insulin treatment reduced the pancreatic tissue concentration of insulin, insulin-IR, and GLUT2-IR in pancreatic islets in hypoglycemic rats. Thus, the protection of ␤-cells against streptozotocin in the insulintreated streptozotocin-injected rats might be caused by reduced cellular need for NAD ϩ in combination with reduced cellular uptake of the drug. A combined effect is likely, as changes in GLUT2 expression on ␤-cells in vitro have been shown only to impede the uptake of glucose to a minor degree (23) , and this phenomenon could also be true for the cellular uptake of streptozotocin into ␤-cells in vivo.
The difference in the intensity of GLUT2-IR between insulin-treated rats on day 0 and insulin-treated streptozotocin-injected rats on day 2 may be caused by the ␤-cell toxic effect of streptozotocin, as GLUT2-IR was still present on day 0, although considerably reduced, but it was not detectable 2 days after administration of streptozotocin. Reduced GLUT2-IR on ␤-cells has been observed previously in hypoglycemic rats with insulinoma (3, 5) and in experimental type II diabetic rats neonatally induced with streptozotocin (24) .
The severity of experimental diabetes and its persistence in rats depends on the dose of streptozotocin used (25) . Intraperitoneal injection of streptozotocin in a dose of 45 mg/kg is known to cause a transient state of diabetes (26) , and spontaneous recovery from experimental diabetes within 36 weeks in rats injected with streptozotocin in doses up to 50 mg/kg has previously been reported (27) . However, low dose insulin treatment of rats injected with 50 mg/kg streptozotocin was previously shown to accelerate the time course for recovery from experimental diabetes to 2 weeks (28). This effect was suggested to be caused by the prevention of hyperglycemia, which was proposed per se to have a harmful effect on ␤-cells (28) . In contrast, ip injection of 60 mg/kg streptozotocin into rats has been shown to induce a persistent diabetic state (26, 29) . We used the high dose of streptozotocin (60 mg/kg) and were still able to significantly protect ␤-cells with insulin pretreatment.
The group of insulin-treated streptozotocin-injected rats in the present study was hypoglycemic 3 days before the injection of streptozotocin. To test the significance of short term hypoglycemia, another group of rats was treated with the same dose of insulin from days Ϫ1 to 1 and injected with streptozotocin on day 0. These rats were hypoglycemic from days 0 -3 and, thus, at the time of streptozotocin injection. However, they became and remained hyperglycemic from day 5, which indicates that insulin pretreatment should be longer than 1 day to prevent the diabetogenic action of streptozotocin.
In the present study, the concentration of immunoreactive insulin in the pancreatic tissue samples from streptozotocindiabetic rats was markedly reduced on day 21 compared to levels in INSϩSTZ, INS, and CTRL rats. In the INSϩSTZ group, the mean pancreatic concentration of insulin on day 21 was one third of that in the CTRL group, but 80 times higher than the pancreatic concentration of insulin in the STZ group. Immunohistochemical examination of the pancreatic islets from the INSϩSTZ rats revealed a fairly large number of insulin-IR ␤-cells, in contrast to the absence of insulin-IR in islets from STZ rats. The amount of glucagon-IR cells was increased in islets from STZ rats compared to those in INSϩSTZ, INS, and CTRL rats. Likewise, the pancreatic glucagon concentration was significantly higher in diabetic rats. However, the amount of enteroglucagon was even higher in the diabetic rats. This was probably caused by hyperphagia, because an increased amount of nutrients in the distal gut is known to stimulate the secretion of enteroglucagon (30) .
Streptozotocin-induced diabetes in laboratory animals has been widely used for research on diabetes and its long term complications. Control animals in these studies are usually injected with citrate buffer solution. However, streptozotocin is known to possess pharmacological effects other than its diabetogenic property (31) (32) (33) , and extrapancreatic actions of streptozotocin cannot be excluded. The presence of GLUT2 in liver and kidney might explain the long term complications seen with hepatic and renal tumors in rodents treated with streptozotocin (26, 34) . Because of the extrapancreatic effects of streptozotocin, it may be difficult to distinguish effects secondary to diabetes from those secondary to strep- tozotocin per se. Therefore, we propose that animals protected with high doses of insulin and then injected with streptozotocin, as described in the present work, could be used in future diabetes studies in which streptozotocin is employed. The control group will not become diabetic, yet any extrapancreatic actions of streptozotocin will be comparable in the control and diabetic groups.
In conclusion, the present report suggests that reduced expression of GLUT2, perhaps in combination with reduced cellular activity of ␤-cells at the time of the administration of streptozotocin may prevent the diabetogenic action of streptozotocin.
